Preeclampsia Clinical Trial
Official title:
Randomized Clinical Trial for Effectiveness of Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure
The postpartum period represents a stage of the pregnancy-puerperal still rarely addressed
scientifically. There are no reports in the literature and concrete enough to elucidate
important issues, especially in the field of hypertension and pregnancy.
Searches based on current evidence concentrate their focus on the diagnosis of hypertensive
disorders and treatment of these diseases maternofetais repercussions. However, the
prognosis in the short and long term, as the BP outcome in mothers with severe preeclampsia,
the most effective treatment for the control of hypertensive crisis and metabolic and
cardiovascular events after two years of termination of pregnancy require further
clarification.
The main idea for developing this research came from the clinical experience with the use of
captopril in Obstetric ICU IMIP. This drug has long been used in postpartum women with
severe preeclampsia or chronic hypertension exacerbated by pregnancy for control of
hypertensive crisis and keeping pressure levels. Following the technical standards of the
institution and during his administration, there were reports of side effects such as dry
cough and nausea, beyond the threshold dose of 150mg daily captopril was easily achieved
hindering control the use of hypotensive.
Alternative therapy, clonidine began to be used in mothers with some restriction on the use
of ACE inhibitors and its hypotensive effect for peak pressure was satisfactory. What is not
known yet is how long clonidine reduces high blood pressure and how long to leave stabilized
compared to the use of captopril.
There are no reports in the literature databases, no randomized clinical trials that prove
the effectiveness of clonidine for the treatment of hypotensive pressure peaks in this
particular group of patients, even in comparison with other classes of antihypertensive
drugs, especially captopril, to this purpose.
The investigators' primary assumption is that clonidine has better effectiveness in
decreasing the frequency of pressure peaks when compared with captopril.
The postpartum period represents a stage of the pregnancy-puerperal still rarely addressed
scientifically. There are no reports in the literature and concrete enough to elucidate
important issues, especially in the field of hypertension and pregnancy.
Searches based on current evidence concentrate their focus on the diagnosis of hypertensive
disorders and treatment of these diseases maternofetais repercussions. However, the
prognosis in the short and long term, as the BP outcome in mothers with severe preeclampsia,
the most effective treatment for the control of hypertensive crisis and metabolic and
cardiovascular events after two years of termination of pregnancy require further
clarification.
The main idea for developing this research came from the clinical experience with the use of
captopril in Obstetric ICU IMIP. This drug has long been used in postpartum women with
severe preeclampsia or chronic hypertension exacerbated by pregnancy for control of
hypertensive crisis and keeping pressure levels. Following the technical standards of the
institution and during his administration, there were reports of side effects such as dry
cough and nausea, beyond the threshold dose of 150mg daily captopril was easily achieved
hindering control the use of hypotensive.
Alternative therapy, clonidine began to be used in mothers with some restriction on the use
of ACE inhibitors and its hypotensive effect for peak pressure was satisfactory. What is not
known yet is how long clonidine reduces high blood pressure and how long to leave stabilized
compared to the use of captopril.
There are no reports in the literature databases, no randomized clinical trials that prove
the effectiveness of clonidine for the treatment of hypotensive pressure peaks in this
particular group of patients, even in comparison with other classes of antihypertensive
drugs, especially captopril, to this purpose.
The investigators' primary assumption is that clonidine has better effectiveness in
decreasing the frequency of pressure peaks when compared with captopril.
A triple blind randomized clinical trial will be conducted. Postpartum women with
hypertensive disorders of pregnancy, admitted to the obstetric ICU of IMIP will be included
in the research. After inclusion in the study, drugs for for very high blood pressure,
according to randomization(captopril and clonidine)will be used. clonidine and captopril are
administered at a dose of 25mg and 0.1mg respectively. If there is no control of blood
pressure in 20 minutes new hypotensive doses will be administered until a total of 150mg/day
(six tablets) and Captopril 0.6 mg / day (six tablets) clonidine. After exceeded the allowed
dose, other drugs may be associated. Initially, nifedipine (30mg/day to 60mg/day) according
to the service routine. The goal of intervention is to maintain a systolic blood pressure
below 170mmHg and diastolic pressure below 110mmHg, with the lowest possible dose. Thus,
these medications will be increased should the need arise, according to measurements taken
daily by the attending physician and the nursing staff.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03510286 -
Validation of a PrCr Dipstick Diagnostic Test in Ghana
|
||
Recruiting |
NCT03313024 -
Berlin-Brandenburg Pregnancy Cohort
|
||
Active, not recruiting |
NCT04990141 -
Molecular Screening Method for Preeclampsia (PREMOM)
|
||
Completed |
NCT02147626 -
Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia
|
N/A | |
Not yet recruiting |
NCT05999851 -
Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy
|
N/A | |
Recruiting |
NCT02923206 -
Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis
|
N/A | |
Completed |
NCT02854501 -
Second Trimester Maternal Serum Homocysteine Levels and Uterine Artery Doppler for Prediction of Preeclampsia and Placentation Disorders
|
||
Completed |
NCT02384226 -
User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study
|
||
Terminated |
NCT02558023 -
The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine
|
Phase 3 | |
Not yet recruiting |
NCT02541110 -
Prediction of Preeclampsia & Other Obstetric Complications by Serum Homocysteine & Doppler
|
N/A | |
Completed |
NCT02554604 -
Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies
|
||
Withdrawn |
NCT05016440 -
Lisinopril for Renal Protection in Postpartum Preeclamptic Women
|
N/A | |
Recruiting |
NCT02337049 -
Preeclampsia Subtypes and Surrogate Markers of CVD Risk
|
N/A | |
Recruiting |
NCT02247297 -
Pancreatic Stone Protein (PSP) in Pregnant Women
|
||
Completed |
NCT02238704 -
Cornell University-Micronutrient Initiative Calcium Supplementation Study
|
N/A | |
Completed |
NCT01195441 -
Prediction and Prevention of Preeclampsia by First Trimester Ultrasound
|
N/A | |
Withdrawn |
NCT01179542 -
The Involvement of Eukaryotic Translation Initiation Factor 4E (eIF4E) in Human Placental Implantation and in the Pathological Pregnancies: Preeclampsia and IUGR
|
N/A | |
Completed |
NCT00456118 -
Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies
|
||
Recruiting |
NCT00117546 -
Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia
|
Phase 4 | |
Completed |
NCT00787241 -
Platelet Count Trends in Pre-eclamptic Parturients
|
N/A |